Arcturus Therapeutics Holdings Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +8.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.07 | $-0.84 | +21.5% | Beat | |
| Q1 FY26 | $-1.14 | $-0.95 | +16.7% | Beat | Q1 FY26 call |
| Q4 FY25 | $-0.92 | $-1.03 | -12.0% | Miss |
Back to ARCT overview · ARCT holders · ARCT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.